EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform
Curve’s innovative mammalian cell drug discovery platform to enable identification and optimisation of novel small molecule drug candidates against MSD targets Potentially game-changing platform enables
Macomics Brings on Five Additional Advisors with Internationally Renowned Immunology and Clinical Oncology Expertise
Edinburgh and Cambridge, UK, 24 January 2022 – Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has added
Apellis and Sobi Announce EU Approval of Aspaveli® (pegcetacoplan) for Treatment of PNH
The first targeted C3 therapy approved in the EU Approval based on results from head-to-head PEGASUS Phase 3 study where Aspaveli demonstrated superiority to eculizumab
Leucid Bio and Lonza Enter Strategic Collaboration to Leverage the Cocoon® Platform for Automated Manufacturing of Personalised CAR T-Cells
Leucid will work with Lonza on the Cocoon® Platform for Leucid Bio’s Phase I/II clinical studies with its lead candidate, LEU-011, for the treatment of
NodThera Announces Progress of NT-0796, a Novel NLRP3 Inflammasome Inhibitor, into a Phase 1 First-in-Human Study
-Study of lead candidate to provide important information on safety, pharmacokinetics and pharmacodynamics to inform further clinical development in chronic inflammatory diseases–Highlights continued progress advancing
Epidarex’s company-building model continues to deliver with Dunad’s $1.3 billion strategic collaboration with Novartis
Epidarex-built start-up signs major global development partnership within 18 months of launch. Epidarex portfolio company will receive $24 million in an upfront payment and equity
Leucid Bio Raises £11.5M in Series A Financing to Develop Next Generation of Innovative Chimeric Antigen Receptor T cell (CAR-T) Therapies
London, UK – 21 October 2021 – Leucid Bio (“Leucid” or the “Company”), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, today announces
Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
September 9, 2021 OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of